Improve Medical Instruments Co Ltd
Improve Medical Instruments Co Ltd designs, develops, and sells advanced medical equipment and technology, primarily in the healthcare services and equipment sector.
Business. Improve Medical Instruments Co Ltd (300030.SZ) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of medical devices. It is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Improve Medical Instruments Co Ltd (300030.SZ) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of medical devices. It is headquartered in China and is primarily listed on the Shenzhen Stock Exchange. Specific details regarding operating segments or geographic revenue breakdowns are not available.
Improve Medical Instruments Co Ltd has a debt-to-equity ratio of 0.48, indicating a relatively conservative capital structure. However, the company reported negative net income of -2,084,430 and negative operating income of -1,418,860, which suggests financial stress. The operating cash flow of 17,229,410 is positive, but the capital expenditure of -33,269,490 indicates significant investment in long-term assets.
The company's return on equity is -0.29%, and return on assets is -0.16%, both of which are below the industry median for Advanced Medical Equipment & Technology. These metrics suggest that the company is not generating returns that meet the expectations of its equity and asset base.
Geographically, the company's revenue is concentrated in China, with no significant international exposure disclosed. The company operates in a single business segment, which may increase its vulnerability to regional economic or regulatory changes.
The company's revenue for the latest period is 152,006,730, and the outlook for the current fiscal year is uncertain due to the negative net income and operating income. The capital expenditure of -33,269,490 suggests a focus on long-term growth, but the negative net cash position after subtracting total debt raises concerns about liquidity.
The company faces medium liquidity risk due to its negative net cash position after subtracting total debt. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares. However, the negative net income and operating income may impact the company's ability to maintain its current capital structure without issuing additional shares.
Recent filings and transcripts indicate that the company is investing in new product development and expanding its market reach. However, the financial results suggest that these investments have not yet translated into profitability. The company's management has not disclosed any specific strategies to address the current financial challenges.
- The company has a negative return on equity and return on assets, indicating poor profitability.
- The company's capital structure is relatively conservative, but its negative net income and operating income suggest financial stress.
- The company's revenue is concentrated in China, increasing its exposure to regional economic and regulatory risks.
- The company is investing in long-term assets, but this has not yet translated into profitability.
- The company faces medium liquidity risk due to its negative net cash position after subtracting total debt.
Bull / Bear case
Generated · model-assistedReturn on equity of -0.3% exceeds the cohort median of -4.7%, showing relatively better capital efficiency.
Free cash flow turned positive to 19.5 million, reversing a 143.4 million deficit from the prior period.
Dilution risk is assessed as low, suggesting limited immediate threat to shareholder equity value.
Debt-to-equity ratio of 0.48 is in the bottom quartile, exceeding the cohort median of 0.06.
Credit risk is flagged as high, indicating significant potential for financial distress or default.
Cash conversion of -8.27 is in the bottom quartile, far worse than the cohort median of 0.79.
Liquidity risk is rated medium, suggesting potential challenges in meeting short-term financial obligations.
In focus — financials by report
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 644.6M, −9,3% YoY; Operating income +79,7% YoY.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 644.6M, −9,3% YoY
- ▍Operating income +79,7% YoY
- ▍Net income +68,1% YoY
- ▍Free cash flow +69,1% YoY
- ▍Net margin -9.8%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 710.8M, −11,1% YoY; Operating income −817,7% YoY.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 710.8M, −11,1% YoY
- ▍Operating income −817,7% YoY
- ▍Net income −1 167,9% YoY
- ▍Free cash flow −732,2% YoY
- ▍Net margin -27.9%
Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 799.8M; Operating income UNKNOWN ERROR IN UNIVERSE PROCESSING 29.8M.
- ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 799.8M
- ▍Operating income UNKNOWN ERROR IN UNIVERSE PROCESSING 29.8M
- ▍Net margin 2.3%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Improve Medical Instruments Co Ltd Market data — financials · 2026-05-26